BioSpace News Archive

Genekam Biotechnology AG, Germany has developed a plasma therapy accelerator called SARS-Hunter, which gives possibility to hospitals to isolate the antibodies from plasma to be given as therapy and increases the chances of success of treatment, while reducing the side effects of plasma therapy given today.

Hamilton Thorne Ltd. (TSX-V: HTL) (“Hamilton Thorne” or the “Company”), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, is pleased to announce that it has closed a non-brokered private placement offering (the “Offering”) of common shares of the Company (“Shares”)

EpicentRx, a next-generation clinical immuno-oncology company, today announced the appointment of physician, scientist and businessman Tony Reid, M.D., Ph.D., as the company’s chief executive officer.

BIOREM Inc. (TSX-V: BRM) (“BIOREM” or “the Company”) announces that due to circumstances created by the Covid-19 pandemic, it will be postponing its reporting of the Company’s interim consolidated financial statements, accompanying management’s discussion and analysis, and related CEO and CFO certifications for the three months ended March 31, 2020

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Jefferies 2020 Global Healthcare Conference, held virtually, on Wednesday, June 3, 2020.

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced that the company will present new data in abstracts to be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, which will be held May 29-31, 2020.

NANOBIOTIX (Paris:NANO)(Euronext: NANO - ISIN: FR0011341205 – the “Company”), today announced new data from the expansion part of its phase I trial, evaluating the potential of first-in-class NBTXR3 activated by radiation therapy to improve treatment outcomes for elderly patients with locally advanced head and neck cancer ineligible for chemotherapy or intolerant to cetuximab.

Treos Bio Limited, a clinical stage biopharma company developing precision peptide cancer immunotherapies, today presented positive final data from a Phase I/II study of PolyPEPI1018, its off-the-shelf multi-peptide treatment, in microsatellite stable metastatic colorectal cancer (MSS mCRC) patients during an online poster presentation released today at the 2020 ASCO Annual Meeting.

The U.S. Food and Drug Administration today granted approval to Oriahnn (an estrogen and progestin combination product consisting of elagolix, estradiol and norethindrone acetate) capsules, co-packaged for oral use, for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.

MYR Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization (CMA) for the medicinal product HEPCLUDEX® (bulevirtide, formally known as Myrcludex B).